Zevra Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present at the following investor conferences in New York, NY.

• Cantor Global Healthcare Conference Fireside chat on Wednesday, September 9, 2026, at 9:10 a.m. ET

• Fireside chat on Wednesday, September 9, 2026, at 9:10 a.m. ET

• Morgan Stanley 24 th Annual Global Healthcare Conference Fireside chat on Monday, September 14, 2026, at 5:35 p.m. ET

• Fireside chat on Monday, September 14, 2026, at 5:35 p.m. ET

• H.C. Wainwright 28th Annual Global Investment Conference Fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET

• Fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET

Additionally, management will be available for one-on-one meetings with registered conference attendees. Links to the live webcasts will be accessible on the “ Events & Presentations ” page in the Investor Relations section of Zevra’s website at investors.zevra.com.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding its ability to advance therapies from development to market and to deliver long-term value. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.